bindarit has been researched along with Chickungunya Fever in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Foo, SS; Forwood, MR; Herrero, LJ; Hueston, L; Lulla, A; Mahalingam, S; Merits, A; Sims, NA; Taylor, A; Walsh, NC | 1 |
| Anantapreecha, S; Guglielmotti, A; Mahalingam, S; Rolph, MS; Rulli, NE; Srikiatkhachorn, A | 1 |
2 other study(ies) available for bindarit and Chickungunya Fever
| Article | Year |
|---|---|
Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.
Topics: Adult; Aged; Animals; Bone Density Conservation Agents; Bone Resorption; Chemokine CCL2; Chikungunya Fever; Disease Models, Animal; Female; Humans; Indazoles; Male; Mice, Inbred C57BL; Middle Aged; Propionates | 2015 |
Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis.
Topics: Alphavirus Infections; Animals; Arthritis, Infectious; Chemokine CCL2; Chikungunya Fever; Chikungunya virus; Humans; Indazoles; Interferon-gamma; Mice; Mice, Inbred C57BL; Models, Animal; Myositis; Propionates; Tumor Necrosis Factor-alpha; Viral Load | 2011 |